EMSY

Across TCGA pan-cancer cohorts, EMSY mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EMSY data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EMSY mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EMSY expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where EMSY mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.132	1.000	.010	38	view →
LUAD	OS	Median	II,III,IV	1.000	0.433	.005	13	view →
LSCC	OS	Median	All	0.881	0.760	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

EMSY–HNSC (OS)

Open the HNSC breakdown →